AcouSort extends collaboration agreement with Japanese Life Science partner

Report this content

AcouSort has extended its cooperation agreement with a major Japanese industrial player regarding the leasing of a new AcouWash 2 system and continuing the ongoing application support. The first agreement was signed in 2019 and is now being extended for yet another year. The extension will generate revenue for AcouSort of EUR 35 000 in 2022.

Since 2019, AcouSort has worked closely with the research department of a Japanese Life Science company. The collaboration has meant, among other things, that AcouSort has successfully optimized the AcouWash system and developed an application for cell separation that is required to enable the Japanese company's development of new diagnostic tests. The new agreement is an extension of what AcouSort and the customer initiated in 2019 and includes upgrading to the new AcouWash 2 system besides technical and application support through 2022.

– It is gratifying that the cooperation continues to develop and that the Japanese company has decided to both extend the previous agreement and also upgrade their AcouWash system to the new model. We are now looking forward to another exciting year where we will have the opportunity to further deepen the collaboration and continue to contribute with the expertise necessary to effectively develop their diagnostic tests, says AcouSort's CEO Torsten Freltoft.

In recent years, AcouSort has had similar collaborative projects with various Life Science companies and has seen the importance of being involved early in the development. In order to attract new OEM customers and develop more OEM products, AcouSort needs engaging in such collaborations early to eventually be a partner during product development ultimately ensuring a smooth transition from product development to commercial production.


For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854



About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.


Documents & Links